Arm B triple therapy plus polaprezinc 150 mg twice daily, 	Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm C triple therapy alone	The incidence of adverse events	21199	21299	The incidence of adverse events in Arm B was much higher than in Arms A (P = 0.04) and C (P = 0.02).
Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm B triple therapy plus polaprezinc 150 mg twice daily, Arm C triple therapy alone	baseline	abdominal pain, acid reflux, belching, heartburn, bloating, nausea, and vomiting	18379	18609	Symptoms included abdominal pain, acid reflux, belching, heartburn, bloating, nausea, and vomiting. All three groups exhibited significant symptom improvement at day 7, 14, and 28 after treatment compared to baseline (P < 0.0001).
Arm B triple therapy plus polaprezinc 150 mg twice daily, 	Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm C triple therapy alone	The incidence of adverse events	1582	1691	The adverse event rate for Arm B (5.1%) was higher than for Arms A (2.8%) (P = 0.04) and C (1.9%) (P = 0.02).
Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm B triple therapy plus polaprezinc 150 mg twice daily,	Arm C triple therapy alone	The rate of H. pylori eradication	1013	1138	rate of H. pylori eradication was significantly higher for Arms A (77.0%) and B (75.9%) compared to Arm C (58.6%) (P < 0.01),
Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm B triple therapy plus polaprezinc 150 mg twice daily,	Arm C triple therapy alone	The rate of H. pylori eradication	17780	18052	The difference of H. pylori eradication rates between polaprezinc combined with triple therapy and triple therapy alone can further increase to reach 19.7% (Arm A vs. Arm C, P < 0.01, 95% CI [7.7–31.8]) and 21.9% (Arm B vs Arm C, P < 0.01, 95%CI [9.9–34.0]), respectively.
